School of Biomedical Engineering, Science and Health Systems Biomedical Technology Showcase, 2006



Drexel E-Repository and Archive (iDEA) <u>http://idea.library.drexel.edu/</u>

Drexel University Libraries www.library.drexel.edu

The following item is made available as a courtesy to scholars by the author(s) and Drexel University Library and may contain materials and content, including computer code and tags, artwork, text, graphics, images, and illustrations (Material) which may be protected by copyright law. Unless otherwise noted, the Material is made available for non profit and educational purposes, such as research, teaching and private study. For these limited purposes, you may reproduce (print, download or make copies) the Material without prior permission. All copies must include any copyright notice originally included with the Material. **You must seek permission from the authors or copyright owners for all uses that are not allowed by fair use and other provisions of the U.S. Copyright Law.** The responsibility for making an independent legal assessment and securing any necessary permission rests with persons desiring to reproduce or use the Material.

Please direct questions to archives@drexel.edu



Effects of Encapsulated BDNF-Producing Fibroblasts on **Dorsal Root Ganglia Neurite Growth**

Nicola L. Francis, Margaret A. Wheatley

School of Biomedical Engineering, Science & Health Systems, Drexel University, Philadelphia PA, 19104

ABSTRACT

Fibroblasts genetically engineered to produce Brain-Derived Neurotrophic Factor (FB/BDNF) have been shown to promote axonal regeneration in the injured spinal cord of an immune-suppressed rat. To avoid immune suppression and protect the cells from the host immune response, FB/BDNF were encapsulated in various alginate gels. BDNF secreted by the fibroblasts was able to diffuse out of the alginate and remain bioactive, stimulating significantly more neurite growth than alginate without encapsulated fibroblasts. A BDNF concentration gradient was also shown to guide DRG neurite growth towards the source. These positive neurotrophic effects show promise as a repair strategy for spinal cord injury.

BACKGROUND

Spinal cord injury (SCI)

- Affects nearly 250,000 people in the U.S.
- · Approximately 11,000 new cases every year Can lead to loss of sensation and motor function: chronic pain:
- spasticity; and bowel, bladder, and sexual dysfunction
- · Effects caused by death of neurons that cannot be replaced, poor regenerative capacity of surviving neurons, damaged CNS environment is inhospitable for growth
- · Ex vivo gene therapy (genetically engineering cells to express a transgene) is a promising strategy for SCI repair, but immune suppression is needed
- · Method needed to provide benefits of ex vivo gene therapy without suppressing immune system

Alginate:

- · Linear polysaccharide derived from seaweed
- · Consists of 1,4-linked _-L-guluronic acid and _-D-mannuronic acid monomers
- · FDA 'Generally Recognized as Safe' Status
- · Nontoxic, biocompatible, easy to process into various shapes, capable of immobilizing biomolecules (such as BDNF-producing fibroblasts)
- · Coating with polypeptides will control porosity, stability, and isolation barrier from the immune system create an



Alginate monomer structure

Schematic of spinal cord injury

OBJECTIVE

To develop a graft suitable for implantation into the injured spinal cord that will:

- Provide a favorable substrate for neuronal adhesion and growth
- Facilitate the use of ex vivo gene therapy without host immune suppression Promote the growth and directional guidance of neurons with a concentration gradient of growth factors

MATERIALS AND METHODS

Discs:

 BDNF-producing fibroblasts (FB/BDNF) resuspended in alginate

•Alginate mixed with CaCO₂-GDL solutions or CaSO₄ slurry ·Mixture shaken and poured into culture plates ·Discs coated with poly-L-ornithine (PLO) and laminin

Fibers

 FB/BDNF resuspended in alginate ·Alginate injected into CaCl₂ solution Fibers coated with PLO and laminin

Dorsal root ganglia (DRGs) removed from 10-day old chick

embryos •DRGs cultured on alginate and observed for up to 72 hours

DRG NEURITE GROWTH





Culture medium + recombinant BDNF





Plain alginate fibers

DRG Neurite Extension with Alginate Fibers Medium Medium+BDN FB Medium Plain Fiber EB Eibers



FB/BDNF alginate fibers Alginate with FB/BDNF promoted significantly more neurite growth

than plain alginate fibers (not containing FB/BDNF) (p<0.05)

 Statistically similar neurite lengths with supplemental recombinant BDNF (positive control #1), medium from FB/BDNF in culture (positive control #2), and alginate encapsulated FB/BDNF (p>0.05)

ALGINATE COMPARISON



CaCO₂-GDL discs promoted significantly more neurite growth than CaSO₄ discs (p<0.001) ·CaCl₂ and CaCO₃-GDL alginates are suitable for use as a DRG growth substrate ·Choosing between the two depends on needs: gelation speed, uniformity, desired shape

BDNF CONCENTRATION GRADIENT



·Concentration gradient formed by covering DRGs and FB/BDNF alginate fibers with 1% agarose ·Agarose slowed the diffusion rate of BDNF and more closely resembled an in vivo environment ·DRGs sprouted neurites under agarose Neurites grew and turned towards alginate fibers ·FB/BDNF alginate fibers promoted greater directional guidance of neurites than plain alginate fibers (p<0.05)

Growth of DRG neurites towards source of BDNF (100x)

CONCLUSIONS

- ·BDNF secreted by fibroblasts able to diffuse out of alginate and remain bioactive, stimulating neurite growth
- •Alginate-encapsulated FB/BDNF (mean neurite length = 306.4 ± 60.72 _m) promoted significantly more DRG neurite growth than alginate without FB/BDNF (mean neurite length = 223.0 ± 65.46 m) ·Alginate not containing FB/BDNF has neurotrophic properties
- •No neurite growth after 24 h suggests an inhibitory interaction between CaSO₄ alginate, encapsulated FB/BDNF, and DRGs
- ·CaCl₂ alginate and CaCO₃-GDL alginate stimulated significantly more neurite outgrowth than CaSO, alginate

·BDNF concentration gradient guided growth of DRG neurite towards the source

FUTURE WORK

•Evaluate effects of FB/NT-3 (neurotrophin-3) on DRG neurite growth •Evaluate synergy of FB/BDNF and FB/NT-3 on DRG neurite growth Vary concentration gradients in alginate to find optimum concentration for FB survival and DRG growth

•Quantify release of BDNF and compare to release from YIGSR-coated alginate

In vivo testing of alginate graft



